- ISIN
- US5019761049
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Feb 8, 2024
Highlights
- Market Cap
- $443.81M
- Enterprise Value
- $422.54M
- EPS (TTM)
- -$3.11
- Gross Profit (TTM)
- -$1.30M
- EBITDA (TTM)
- -$158.20M
- Year Range
- $2.80 - $13.67
- Target Price
- $32.67
- ROA (TTM)
- -60.85%
- ROE (TTM)
- -79.97%
- Avg. Volume (1M)
- 1M
- Avg. Volume Value (1M)
- $9.16M
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
KYTX Performance Chart
Kyverna Therapeutics, Inc (KYTX) is down 22.3% since the beginning of the year. At $7 per share, KYTX is trading 46.6% below its 52-week high of $14.
Loading charts...
Compare this symbol against anything
Returns By Period
Kyverna Therapeutics, Inc (KYTX) has returned -22.34% so far this year and 112.21% over the past 12 months.
Kyverna Therapeutics, Inc
- 1D
- -2.54%
- 1M
- -17.89%
- 6M
- -8.86%
- YTD
- -22.34%
- 1Y
- 112.21%
- 3Y*
- —
- 5Y*
- —
- 10Y*
- —
- ALL TIME*
- -46.45%
Benchmark (S&P 500 Index)
- 1D
- 0.70%
- 1M
- 0.09%
- 6M
- 7.94%
- YTD
- 9.41%
- 1Y
- 20.07%
- 3Y*
- 17.84%
- 5Y*
- 11.25%
- 10Y*
- 13.26%
- ALL TIME*
- 8.09%
KYTX Monthly Returns History
Based on dividend-adjusted daily data since Feb 8, 2024, KYTX's average daily return is -0.06%, while the average monthly return is -2.39%.
Historically, 50% of months were positive and 50% were negative. The best month was Sep 2025 with a return of +61.7%, while the worst month was Jun 2024 at -40.1%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 5 months.
On a daily basis, KYTX closed higher 47% of trading days. The best single day was Oct 8, 2025 with a return of +32.7%, while the worst single day was Jun 14, 2024 at -34.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.79% | 2.50% | 5.12% | 1.97% | -3.18% | 4.58% | -18.07% | -22.34% | |||||
| 2025 | -13.37% | -12.35% | -32.04% | 19.69% | 10.39% | 20.39% | 16.29% | 3.92% | 61.73% | 16.17% | 10.04% | 22.56% | 151.34% |
| 2024 | -20.67% | -8.58% | -39.05% | -17.24% | -40.14% | 15.47% | -7.27% | -39.10% | -2.25% | 20.71% | -35.18% | -89.08% |
Benchmark Metrics
Kyverna Therapeutics, Inc has an annualized alpha of -36.45%, beta of 1.75, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since February 08, 2024.
- This stock participated in 321.30% of S&P 500 Index downside but only -42.98% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -36.45%
- Beta
- 1.75
- R²
- 0.08
- Upside Capture
- -42.98%
- Downside Capture
- 321.30%
Return for Risk
Risk / Return Rank
KYTX ranks 79 for risk / return — above 79% of stocks peers on PortfoliosLab. Its historical combined result is above most peers.
Risk / Return Metrics
The table below present risk-adjusted performance metrics for Kyverna Therapeutics, Inc (KYTX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| KYTX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.38 | ||
| Sortino ratioReturn per unit of downside risk | -0.06 | ||
| Omega ratioGain probability vs. loss probability | 1.24 | 1.25 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 2.83 | 2.00 | +0.82 |
| Martin ratioReturn relative to average drawdown | 5.41 | 8.49 | -3.08 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Kyverna Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Kyverna Therapeutics, Inc was 94.66%, occurring on Apr 16, 2025. The portfolio has not yet recovered.
The current Kyverna Therapeutics, Inc drawdown is 78.69%.
Drawdown | Fall | Recovery | Underwater | Related event |
|---|---|---|---|---|
-94.66%Apr 2025 | 1y 2mo | — | 2y 5moFeb 2024 - now | 2025 selloff2025 |
Drawdown Indicators
| KYTX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.66% | -56.78% | -37.88% |
Max Drawdown (1Y)Largest decline over 1 year | -37.16% | -9.10% | -28.06% |
Max Drawdown (3Y)Largest decline over 3 years | — | -18.90% | — |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -78.69% | -1.58% | -77.11% |
Average DrawdownAverage peak-to-trough decline | -76.32% | -10.70% | -65.62% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 19.41% | 2.14% | +17.27% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Kyverna Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Kyverna Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for KYTX in comparison with other companies in the Biotechnology industry. Currently, KYTX has a P/B value of 2.3. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with KYTX
Add Kyverna Therapeutics, Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with KYTX